Lunfei M. Liu
Yiwu, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
SSGJ-608 in moderate-to-severe plaque psoriasis: a multicenter, randomized, open-label, phase 3 study.
Journal: Frontiers in immunology
Published: February 13, 2026
A multicenter, randomized, double-blinded, placebo-controlled phase III trial to evaluate efficacy and safety of picankibart in moderate-to-severe plaque psoriasis.
Journal: Journal of the American Academy of Dermatology
Published: February 11, 2026
MG-K10, a Long-Acting Anti-IL-4 Receptor Alpha Monoclonal Antibody in Adult Patients with Moderate-to-Severe Atopic Dermatitis.
Journal: Dermatitis : contact, atopic, occupational, drug
Published: November 05, 2025
Early itch relief with ivarmacitinib improves quality of life, working productivity, and sleep quality in patients with moderate-to-severe atopic dermatitis: a post hoc analysis of a phase III trial.
Journal: The Journal of dermatological treatment
Published: September 11, 2025
Safety and efficacy of the selective tyrosine kinase 2/Janus kinase 1 inhibitor TLL-018 in patients with moderate-to-severe chronic spontaneous urticaria with inadequate response to H1 antihistamines: a phase Ib, randomized, double-blind, placebo-controlled pilot study.
Journal: The British journal of dermatology
Published: August 08, 2025
Efficacy and Safety of Extending Dosing Interval of Stapokibart in Patients with Atopic Dermatitis.
Journal: Dermatitis : contact, atopic, occupational, drug
Published: July 25, 2025
A case report of plaque psoriasis comorbid with hidradenitis suppurativa, hepatitis B, and colorectal cancer treated with xeligekimab.
Journal: Frontiers in immunology
Published: June 22, 2025
Denifanstat for moderate-to-severe acne: A Phase 2, randomized, double-blind, placebo-controlled trial.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: December 26, 2024
Efficacy and safety of the triple combination cream in Chinese patients with moderate to severe melasma: A multi-center, randomized, double-blind, three-arm, parallel-group, placebo-controlled clinical trial.
Journal: Chinese medical journal
Published: December 17, 2024
Efficacy and Safety of 611 in Chinese Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Phase II Trial.
Journal: Dermatology and therapy
Published: December 05, 2024
Efficacy and Safety of Generic Fluocinolone Acetonide, Hydroquinone, and Tretinoin Cream Compared With TRI-LUMA for the Treatment of Moderate-To-Severe Melasma in Chinese Patients: A Randomized, Single-Center, Placebo-Controlled Trial.
Journal: Journal of cosmetic dermatology
Published: October 17, 2024
Efficacy and safety of topical finasteride spray solution in the treatment of Chinese men with androgenetic alopecia: A phase III, multicenter, randomized, double-blind, placebo-controlled study.
Journal: Chinese medical journal
Published: July 30, 2024
Last Updated: 09/26/2026